|
29 May 2020 |
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
|
|
29 May 2020 |
ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors
|
|
29 May 2020 |
ENHERTU (fam-trastuzumab deruxtecan-nxki) Demonstrated Meaningful Clinical Activity in Patients With HER2-mutant Non-small Cell Lung Cancer in Interim Analysis of Phase II DESTINY-Lung01 Trial
|
|
29 May 2020 |
ENHERTU (fam-trastuzumab deruxtecan-nxki) Significantly Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial
|
|
29 May 2020 |
ENHERTU (fam-trastuzumab deruxtecan-nxki) Achieved a Tumor Response Rate of 45.3% in Patients With HER2-Positive Metastatic Colorectal Cancer in Phase II DESTINY-CRC01
|
|
29 May 2020 |
Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance
|
|
29 May 2020 |
IMFINZI® (durvalumab) Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial
|
|
29 May 2020 |
IMFINZI plus tremelimumab Demonstrated Promising Clinical Activity and Tolerability in Patients With Advanced Liver Cancer
|
|
29 May 2020 |
KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma
|
|
29 May 2020 |
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
|
|
28 May 2020 |
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study
|
|
28 May 2020 |
MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia
|
|
28 May 2020 |
Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
|
|
28 May 2020 |
Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug
|
|
28 May 2020 |
Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe
|
|
28 May 2020 |
DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK's investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
|
|
28 May 2020 |
Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies
|
|
28 May 2020 |
Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia
|
|
27 May 2020 |
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
|
|
27 May 2020 |
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
|
|
27 May 2020 |
Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
|
|
26 May 2020 |
Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
|
|
26 May 2020 |
Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis
|
|
26 May 2020 |
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies
|
|
26 May 2020 |
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
|
